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ORIGINAL RESEARCH
Effector Memory T cells Are Associated With Atherosclerosis
in Humans and Animal Models
Enrico Ammirati, MD; Domenico Cianﬂone, MD; Viviana Vecchio, BSc; Michela Banﬁ, BSc; Anna C. Vermi, MD; Monica De Metrio, MD;
Liliana Grigore, MD; Fabio Pellegatta, MD; Angela Pirillo, PhD; Katia Garlaschelli, BSc; Angelo A. Manfredi, MD; Alberico L. Catapano, PhD;
Attilio Maseri, MD; Alessio G. Palini, MSc; Giuseppe D. Norata, PhD
Background—Adaptive T-cell response is promoted during atherogenesis and results in the differentiation of na¨ıve CD4+T cells to
effector and/or memory cells of specialized T-cell subsets. Aim of this work was to investigate the relationship between circulating
CD4+T-cell subsets and atherosclerosis.
Methods and Results—We analyzed 57 subsets of circulating CD4+T cells by 10-parameter/8-color polychromatic ﬂow cy-
tometry (markers: CD3/CD4/CD45RO/CD45RA/CCR7/CCR5/CXCR3/HLA-DR) in peripheral blood from 313 subjects derived
from 2 independent cohorts. In the ﬁrst cohort of subjects from a free-living population (n=183), effector memory T cells (TEM:
CD3+CD4+CD45RA−CD45RO+CCR7− cells) were strongly related with intima-media thickness of the common carotid artery,
even after adjustment for age (r=0.27; P<0.001). Of note, a signiﬁcant correlation between TEM and low-density lipoproteins was
observed. In the second cohort (n=130), TEM levels were signiﬁcantly increased in patients with chronic stable angina or acute
myocardial infarction compared with controls. HLA-DR+TEM were the TEM subpopulation with the strongest association with the
atherosclerotic process (r=0.37; P<0.01). Finally, in animal models of atherosclerosis, TEM (identiﬁed as CD4+CD44+CD62L−)
were signiﬁcantly increased in low-density lipoprotein receptor and apolipoprotein E deﬁcient mice compared with controls and
were correlated with the extent of atherosclerotic lesions in the aortic root (r=0.56; P<0.01).
Conclusions—Circulating TEM cells are associated with increased atherosclerosis and coronary artery disease in humans and
in animal models and could represent a key CD4+T-cell subset related to the atherosclerotic process. ( J Am Heart Assoc
2012;1:27-41.)
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T cells play a key role in the immune response observedduring atherogenesis.1,2 In the arterial wall, cholesterol
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accumulation followed by vascular inﬂammation promotes
adaptive T-cell response,3 and results in the differentiation
of na¨ıve CD4+T cells to effector and/or memory cells of spe-
cialized T-cell subsets in secondary lymphoid organs and in the
chemokine-driven recruitment of speciﬁc T-cell and monocyte
subsets into the atherosclerotic plaque.4–7
Most of T cells found in human atherosclerotic lesions
are activated effector and/or memory CD4+ that predominate
over CD8+T cells,8–10 with a speciﬁc antigenic response.6,11,12
The activation of inﬂammatory pathways in atherosclerotic
Editorial on p 3
lesions is reﬂected also in neutrophils, monocytes, and T lym-
phocytes present in peripheral blood,13–16 supporting the con-
cept of a systemic process with local inﬁltration in the arte-
rial wall. In animal models, a CCR7-dependent recirculation
of T cells and monocytes between secondary lymphoid or-
gans and inﬂamed tissues and egression from atherosclerotic
plaques to blood was observed;17–19 suggesting a dynamic pro-
cess that involves local factors (ie, oxidative and shear stress)
and systemic factors (ie, traditional cardiovascular risk factors,
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Figure 1. CD4+T cells subsets: properties and potential role in atherosclerosis.
activation of platelets, and coagulation system).20,21 Of note,
inhibition of chemokine receptors that are involved in the re-
cruitment of circulating T cells into the plaque such as CCR5
and CXCR3,22,23 attenuates atherosclerotic lesion formation in
animal models.24–27
In spite of the strong experimental evidence supporting a
role for T cells in murine atherosclerosis, their clinical signiﬁ-
cance in humans remains limited.28 Therefore, the characteri-
zation of circulating CD3+CD4+T-cell subsets in patients with
different stages of atherosclerosis and with various manifesta-
tions of coronary artery disease (CAD) could contribute to clar-
ify the role of these cells on atherosclerotic plaque formation
and progression. In humans, forefront technologies such as
polychromatic ﬂow cytometry, revealed the presence of hun-
dreds of phenotypically distinct leukocytes in the peripheral
blood with specialized proﬁles and programmed functions that
may reﬂect speciﬁc activation in the immune response, even
in the absence of an overall alteration in total T-cell number.29
Adaptive immune response during atherogenesis involves
the expansion of memory T cells, antigen-experienced T cells,
which (1) elicit stronger and more sustained immune re-
sponse upon antigen reexposure and (2) support the cyto-
toxic function of CD8+T cells. Because antigens associated
with cholesterol-rich lipoproteins promote adaptive immune
response and atherosclerosis in animal models,5 we hypothe-
sized that in subjects with atherosclerotic disease, alterations
in the levels of circulating T-cell subsets that occur, can be
appreciated in peripheral blood.
During atherogenesis, antigens generated directly or in-
directly as a consequence of hypercholesterolemia and pre-
sented by antigen-presenting cells,7 are likely to stimulate
the development of central memory T cells (TCM) and effec-
tor memory T cells (TEM), from na¨ıve (TN) cells. TN, TCM, and TEM
have speciﬁc homing capacities and effector functions, and are
identiﬁable by different expression of surface receptors (see
Figure 1).7,30 Through their expression of CCR7 and CD62L,
TN and TCM preferentially home to T-cell areas of sec-
ondary lymphoid organs and display little immediate effector
functions.7,30 On the other hand, TEM which have lost the con-
stitutive expression of CCR7, express tissue homing receptors
associated with inﬂammation (ie, CCR5 and CXCR3) and dis-
play more readily effector functions.7,30
Aim of this study was to investigate the relationships be-
tween atherosclerosis and 7 main CD4+T-cell subsets with
50 derived T-cell subpopulations, resulting from the expres-
sion of speciﬁcmarkers (CD3/CD4/CD45RO/CD45RACCR7/
CCR5/CXCR3/HLA-DR) investigated by 10-parameter/8-
color polychromatic ﬂow cytometry. We ﬁrst investigated the
association between levels of speciﬁc T-cell subsets with a
surrogate marker of atherosclerosis, that is, the intima-media
thickness (IMT) of the common carotid artery in a free-living
population. Next, we examined the levels of speciﬁc T-cell
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subsets in patients with stable stenotic coronary atherosclero-
sis (ie, chronic stable angina [CSA]) and acute unstable mani-
festations (ie, acute myocardial infarction [AMI]). These analy-
ses identiﬁed circulating TEM as the best T-cell subset associ-
ated with atherosclerotic disease characterized by a signiﬁcant
correlation with lipid proﬁle. We sought to conﬁrm these ﬁnd-
ings in animalmodels by evaluating the correlation of TEM levels
with atherosclerosis extent in the aortic root of apolipoprotein
E and low-density lipoprotein (LDL) receptor deﬁcient animals.
Methods
Study Populations
Institutional Ethics Committees approved the study and in-
formed written consent was obtained from all participating
subjects. The study was conducted according to the standards
of the Declaration of Helsinki and Good Clinical Practice. Blood
samples from 313 subjects from two independent cohort were
analyzed.
Carotid study: This cohort was composed by 183 consec-
utively enrolled subjects from a free-living population during
3 months (September to November 2008) in the context of a
larger observational study named PLIC (Progressione Lesioni
Intimali Carotidee), previously described.31 The clinical and
anthropometrical characteristics of this cohort are presented
in Table 1.
For the study in patients with CAD blood samples were ob-
tained from patients on admission to San Raffaele Scientiﬁc
Institute and Centro Cardiologico Monzino, both in Milan from
December 2007 to June 2009. The control group was made
of 40 control subjects age and sex matched without clinical
and electrocardiographic signs of CAD. Ninety patients with
CAD were divided in a CSA group including 30 patients with
effort angina (lasting more than 3months and without previous
history of unstable angina or AMI) and angiographic evidence
of coronary artery stenosis (>50%) and an AMI group includ-
ing 60 patients. AMI samples were obtained before coronary
angiography and early after the onset of symptoms when the
elevation of troponin I were still minimal (median: 0.4 ng/mL),
thus minimizing the possible confounding effect of myocardial
necrosis.32 A second sample was also obtained from 10 AMI
patients after 24 hours from the acute event to check for vari-
ation of T-cell subsets during the acute phase. The analysis
showed similar levels of these cell subsets (data not shown)
suggesting that, at least in the early hours from the onset of
AMI, perturbations attributable at myocardial necrosis were
limited in the T-cell subsets under investigation. Clinical char-
acteristics and biological parameters of patients with CAD and
control subjects are reported in Table 2.
Biochemical Parameters and IMT Measurement
Measurement of biochemical parameters and clinical out-
come in the patients of the PLIC study has been described
Table 1. Clinical Characteristics and Biological Parameters
of Subjects From the General Population (PLIC Study)
Carotid Study (all subjects)
No. 183
Age (y) 54±14
Male Sex—no. (%) 93 (50.5)
Current smoker no. (%) 43 (23.4)
Hypertension no. (%) 45 (24.8)
Diabetes mellitus no. (%) 14 (7.6)
Hypercholesterolemia no. (%) 31 (16.8)
Systolic blood pressure (mm Hg) 124±18
Diastolic blood pressure (mm Hg) 76±9
BMI (kg/m2) 25.9±3.7
Glicemia (mg/dL) 100±22
Total cholesterol (mg/dL) 217±42
LDL-cholesterol (mg/dL) 142±38
HDL-cholesterol (mg/dL) 56±13
Tryglicerides (mg/dL) 100±55
Creatinine (mg/dL) 0.88±0.17
IMT (mm) 0.67±0.14
WBC (109/L) 6.6±1.2
Lymphocytes (109/L) 2.3±0.4
Data are presented as mean±standard deviation. BMI indicates body mass index; HDL,
high-density lipoprotein; IMT, intima-medial thickness; LDL, low-density lipoprotein;
WBC, whole blood count.
elsewhere.31,33 For IMT, brieﬂy, ultrasound scanning and read-
ing of carotid arteries were performed by a single expert sono-
grapher, using an 8-MHz transducer (Biosound 2000 II sa, In-
dianapolis, IN) with an axial and lateral resolution of 0.385 and
0.500 mm, respectively. The sonographer was blinded to the
subject’s identity. B-mode evaluations are obtained from cap-
tures of the far wall in the ﬁrst centimeter of common carotid
arteries, proximal to the bulb dilation, in lateral projection. Five
standardized points 5, 10, 20, 25, and 30 mm from bulb were
measured in both arteries and averaged to calculate the mean
IMT (IMTm) for each subject. In two scans performed on 75
subjects by the same operator, the mean difference in IMTm
was 0.005±0.002 mm and the variation coefﬁcient equal to
1.93%. The correlation between two scans was signiﬁcant with
r=0.96 (P<0.0001).
Polychromatic Flow Cytometry
Whole blood fromeach subject was collected in EDTA anticoag-
ulated vacutainer tube. Samples were stained and ﬁxed within
the day of collection. We veriﬁed that there were no signiﬁ-
cant differences in the investigated marker levels in samples
stained immediately after collection in comparison to samples
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Figure 2. Identiﬁcation of positive stained cells using the Fluorescence Minus One (FMO) strategy. To appropriately identify positive stained cells
and differentiate them from background autoﬂuorescence for gate inclusion, we used the FMO strategy. The background nonspeciﬁc ﬂuorescence
is collected in the detector assigned to the missing antibody in FMO control. FMO controls are samples that include all the conjugated antibodies
but one. The channel for the missing conjugated antibody is that of the FMO gating control. FMO controls are important for setting thresholds in
cell populations that express a continuous spectrum of numbers of receptors (such as CD45RO, CD45RA, CCR7, CCR5, HLA-DR, and CXCR3) and
allows to better deﬁne the positive cell population in comparison with unstained cells. In fact, although unstained cell populations are centered
close to zero, their width can vary depending on autoﬂuorescence and spillover corrections in different channels. In (A), the plot on the left the
antibody CD45RO-APC conjugated is missing and in the plot on the right the antibody CD45RA-ECD conjugated is missing. In this way, it is
possible to correctly deﬁne the thresholds of CD45RO positive and CD45RO positive cells in the plot in the center. In (B), the same procedure
for the other antibodies used in our experiments. The unstained populations are presented to assess the difference with the positive threshold
identiﬁed with FMO.
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Table 2. Clinical Characteristics and Biological Parameters of Patients with coronary artery disease (CAD) and Matched Controls
Controls CSA AMI P-Value
No. 40 30 60
Age(y) 61 (±9) 64 (±11) 64 (±11) 0.37
Male Sex—no. (%) 32 (80) 22 (73) 46 (77) 0.81
Family history of CAD 17 (43) 12 (40) 20 (33) 0.95
Current smoker 14 (35) 7 (23) 25 (42) 0.23
Hypertension 20 (50) 22 (73) 36 (60) 0.14
Diabetes mellitus 0 (0) 3 (10) 5 (8) 0.14
Hypercholesterolemia 22 (55) 19 (63) 29 (48) 0.40
Troponin I (ng/mL) – – 0.4 (0.1–1.1) –
WBC (109/L) 6.5±1.4 7.9±1.4 11.1±4.0∗ <0.0001
Lymphocytes (109/L) 2.2±0.5 2.2±0.4 2.4±0.6 0.11
Monovessel disease – 11 (37) 22 (37) 0.42
Bivessel disease – 7 (23) 21 (35)
Trivessel disease – 12 (40) 17 (28)
Aspirin 2 (5) 22 (73)∗ 36 (60)∗ <0.0001
Thienopyridine 0 (0) 8 (27)† 14 (23)† 0.003
β-blockers 1 (3) 14 (47)∗ 16 (40)∗ <0.0001
Statins 1 (3) 14 (47)∗ 10 (17)† <0.0001
Ca-blockers 4 (10) 8 (27) 5 (8) 0.04
ACE inhibitors/ARBs 9 (23) 12 (40) 23 (38) 0.19
Nitrates 0 (0) 11 (37)∗ 24 (40)∗ <0.0001
Diuretics 5 (13) 4 (13) 6 (10) 0.87
∗<0.001 vs controls after Bonferroni post hoc test.
†<0.01 vs controls after Bonferroni post hoc test.
ACE indicates angiotensin converting enzyme; ARBs, angiotensin receptor blockers; CAD, coronary artery disease; WBC, whole blood count.
stained up to a maximum 24-hour time interval postsampling
and stored at room temperature. In order to reduce cellular loss
and analysis sampling bias in the specimen, the nowash, whole
blood lyses technique was used. For each specimen, 50 µL of
a mixture of 8 antibodies was added to 100 µL of whole blood
followed by a 20-minute incubation in the dark at room temper-
ature. After staining, the red blood cells were lysed and ﬁxed
with the Immune-prep System (Beckman Coulter). White cells,
diluted in 1 mL total volume were analyzed on a LSR II Flow Cy-
tometer (BD Biosciences) equipped with four lasers and stan-
dard optics. The antibodies were selected to minimize spectral
overlap. Furthermore to reduce the nonspeciﬁc ﬂuorescence
background and optimize the ﬂuorescence signal, we used ap-
propriately titred directly conjugatedmonoclonal antibodies.34
The panel used, consisted of the subsequent cellular surface
markers: CD3 (Paciﬁc Blue-labeled, clone HIT3a, BD Pharmin-
gen), CD4 (APC-Cy7, SK3, BD Biosciences), CCR5/CD195
(PE, 2D7, BD Pharmingen), CXCR3/CD183 (FITC, 49801, R&D
Systems Inc), CCR7/CD197 (PE-Cy7, 3D12, BD Pharmingen),
HLA-DR (Quantum Red, HK14, Sigma-Aldrich), CD45RO (APC,
UCHL1, Caltag), and CD45RA (ECD, 2H4, IOTest, Beckman
Coulter). To appropriately identify positive stained cells and
differentiate them from background autoﬂuorescence for gate
inclusion, we used the Fluorescence Minus One strategy. The
channel for the missing conjugated antibody is that of the
Fluorescence Minus One gating control (Figure 2). Fluores-
cence intensity for each signal measured was standardized
using multiple peak Rainbow calibration particles (Code RCP-
30-5A, Spherotech) to allow reproducible and comparable me-
dian ﬂuorescence intensity throughout the study period, as
previously described.33 We identiﬁed 7 principal T-cell sub-
sets and 50 T-cell subpopulations derived by principal sub-
sets by means of the combination of the surface markers.
All data were acquired in FCS format using FACSDiva Soft-
ware 5.0 (BD Biosciences). Lymphocytes were identiﬁed and
electronically gated on forward and orthogonal light scatter
signals. The ﬂuorescent signals for phenotype analyses were
accumulated for the gated lymphocytes. The instrument raw
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data were stored electronically to a server for archiving and
data processing. Data were processed and analyzed using
FCS Express V3 Research edition (De Novo Software, Inc;
http://www.denovosoftware.com). Cell viability was >99%,
assessed using the Molecular Probes Patented LIVE/DEAD
Viability (Invitrogen) according to the manufacturer
instructions.
Identiﬁcation of T-Cell Subsets in Animal Models
of Atherosclerosis by Flow Cytometry
T cell subsets were investigated in peripheral blood collected
from male mice with apolipoprotein E or LDL receptor de-
ﬁciency (two animal models of atherosclerosis) and control
animals with the same C57Bl6/J background.35 The inves-
tigation conformed to the European Commission Directive
86/609/EEC and was approved by the local committee (Pro-
getto di Ricerca 2009/3). Brieﬂy, at 8 weeks of age, animals
were fed ad libitum with western-type diet (21% fat, 0.15%
cholesterol, and 19.5% casein, Harlan, Bresso, Italy) for 16
weeks except for the group 1 (C57Bl6/J animals that contin-
ued at chow diet). Mice were euthanized with an overdose of
Avertin 2.5% (Aldrich Chemical Co ), followed by cervical dis-
location. Blood samples were collected in EDTA tubes imme-
diately before death and plasma was separated by low-speed
centrifugation at 4◦C. The measurement of plasma lipids was
performed by enzymatic techniques (ABX for Cobas Mira Plus,
Montpellier, France)35 and atherosclerosis was quantiﬁed at
the aortic sinus as described.36 For ﬂow-cytometry analysis,
the following panel of cellular surface markers was used: CD4
(Paciﬁc Blue-labeled, RPA-T4, BD Pharmingen), CD44 (FITC,
IM7, BD Pharmigen), and CD62L (APC, mMEL-14, BD Pharmi-
gen).
Monitoring T-Cell Subsets in Subjects Who
Underwent Tetanus Vaccination
For this study, blood samples from three control subjects that
performed booster shots of tetanus vaccine for personal rea-
sons (travel to a zone at increased risk for tetanus) were taken.
The subjects signed an informed consent. Subjects were sam-
pled (4 mL of whole blood in EDTA each time) the day of the
vaccination (before exposure), and 2, 7, 14, and 21 days after
exposure. All three subjects were previously vaccinated. They
received a single dose of 40 International Units of tetanus tox-
oid (ANATETALL, Novartis Vaccines & Diag) by intramuscular
injection.
Statistical Analysis
Results are reported as mean±standard deviation (SD) or me-
dian, ﬁrst to third interquartile on the basis of normal or nonnor-
mal distribution respectively (Shapiro-Wilk normality test was
performed). Group differences in continuous variables were
determined by using Student’s t test or one-way analysis of
variance with Bonferroni’s multiple comparison test for nor-
mally distributed values and Mann-Whitney U test or Kruskall-
Wallis test with Dunn’s multiple comparison test as appro-
priate. Analysis of variance univariate analysis was performer
between all variables and IMT. Multiple stepwise regression
analysis was performer with IMT as the dependent variable,
and by entering the independent variable with the highest
partial correlation coefﬁcient at each step. Associations are
summarize using correlation coefﬁcients, Pearson correlation
coefﬁcient is shown for variables normally distributed while
Spearman rank correlation coefﬁcient is shown for variables
that were not normally distributed. Group differences or corre-
lations with P<0.05 were deemed as statistically signiﬁcant.
GraphPad Prism 4 and SPSS Statistics 17.0 softwares were
used for analysis.
Results
Identiﬁcation of Seven Main CD3+CD4+T-Cell
Subsets and 50 Derived T-Cell Subpopulations
We identiﬁed seven principal T-cell subsets by 10-
parameter/8-color ﬂow cytometry analysis: na¨ıve
T cells (called TN deﬁned as CD3+CD4+CD45RA+
CD45RO−CCR7+), memory T cells (TM, deﬁned as
CD3+CD4+CD45RA−CD45RO+), central memory T cells
(TCM, deﬁned as CD3+CD4+CD45RA−CD45RO+CCR7+)
and effector memory T cells (TEM, deﬁned as
CD3+CD4+CD45RA−CD45RO+CCR7−), HLA-DR+T cells
(CD3+CD4+HLA-DR+), CCR5+T cells (CD3+CD4+CCR5+),
and CXCR3+T cells (CD3+CD4+CXCR3+) (Figure 3). Then,
we described 50 T-cell subpopulations derived from these
principal T cell subsets (see Table 3 for the list of all analyzed
subpopulations). Principal T-cell subsets and subpopulations
were expressed as percentage of total CD3+CD4+T cells.
Antigen Reexposure Can Modify the Composition
of Memory T-Cell Compartment in Humans
As proof of principle in a limited number of subjects, we ana-
lyzed changes in the composition of memory T-cell compart-
ment after antigen reexposure. We demonstrated that our ap-
proach was sensitive enough to clearly identify these modiﬁ-
cations. In particular, antigen reexposure lead to a temporally
limited TEM increase in the peripheral blood of control subjects
vaccinated with tetanus toxoid (For details also concerning TM
and TCM modiﬁcations see Figure 4).
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Figure 3. Gating strategy to identify the principal CD4+T-cell subsets, and some of the T-cell subpopulations. Color dot plot of a representative
subject. Lymphocytes were identiﬁed and electronically gated on orthogonal light scatter signals and CD3 immunopositivity (approximately 30.000
events on CD3 for each sample) (A). Then CD3+CD4+T cells were identiﬁed (B). Gating on CD3+CD4+T cells, memory T cells (TM) were identiﬁed
as CD45RA negative and CD45RO positive (C). In (D), the expression of the chemokine receptor CCR-7 was shown in CD3+T cells. In (E), the
expression of CCR7 deﬁned the na¨ıve T cells (TN) as CD45RA+CD45RO− and CCR7 positive. In (F), the expression of CCR7 is used to deﬁne
central memory T cells (TCM; CCR7 positive) and effector memory T cells (TEM; CCR7 negative). In (G), it is shown the different expression of
chemokine receptors CXCR3, CCR5, and marker of activation HLA-DR in CD3+CD4+CCR7+ T cells, in TN, in TCM and in TEM. TEM have a relative
increased expression of markers of activation and chemokine receptors in comparison with other T-cell subsets. In G are shown some of the T-cell
subpopulations that are considered in further analysis (such as CXCR3+TEM, CCR5+TEM, HLA-DR+TEM).
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Table 3. Description of All T-Cells Subpopulation Analyzed
Levels (% of
CD3+CD4+T Subsets Subpopulations CD3+CD4+)
Naı¨ve
CD45RA+RO−CCR7+
CXCR3+ 1.1 (1.1)
CCR5+ 0.9 (0.8)
HLA-DR+ 0.2 (0.2)
CXCR3+CCR5+ >0.1∗
CXCR3+CCR5− 0.1 (0.1)
CXCR3−CCR5+ >0.1∗
CXCR3+HLA-DR+ >0.1∗
CXCR3+HLA-DR− 1.0 (1.0)
CXCR3−HLA-DR+ >0.1∗
CD45RA+RO−CCR7−† 2.4 (1.7)
CXCR3+ 0.1 (0.1)
Central memory T
CD45RA−RO+CCR7+
CXCR3+ 20.1 (7.3)
CCR5+ 5.2 (3.6)
HLA-DR+ 3.8 (1.9)
CXCR3+CCR5+ 3.1 (2.4)
CXCR3+CCR5− 17.1 (6.1)
CXCR3−CCR5+ 2.2 (1.7)
CXCR3+HLA-DR+ 1.8 (1.1)
CXCR3+HLA-DR− 18.4 (6.9)
CXCR3−HLA-DR+ 2.0 (1.2)
Effector memory T
CD45RA−RO+CCR7−
CXCR3+ 5.2 (2.5)
CCR5+ 0.8 (0.5)
HLA-DR+ 1.0 (0.7)
CXCR3+CCR5+ 2.0 (1.9)
CXCR3+CCR5− 3.9 (2.1)
CXCR3−CCR5+ 0.6 (0.5)
CXCR3+HLA-DR+ 0.4 (0.3)
CXCR3+HLA-DR− 4.2 (2.3)
CXCR3−HLA-DR+ 0.6 (0.4)
CD45RA+RO+‡ 5.6 (3.5-8.5)
CD45RA+RO+CCR7+ 5.2 (3.1-7.8)
CXCR3+ 1.1 (0.8-1.5)
CCR5+ 0.5 (0.3-0.7)
HLA-DR+ 0.1 (0.1)
Continued
Table 3. Continued
Levels (% of
CD3+CD4+T Subsets Subpopulations CD3+CD4+)
CXCR3+CCR5+ 0.4 (0.2–0.5)
CXCR3+CCR5− 0.7 (0.5–1.1)
CXCR3−CCR5+ 0.1 (0.04–0.2)
CXCR3+HLA-DR+ >0.1∗
CXCR3+HLA-DR− 1.0 (0.7–1.4)
CXCR3+HLA-DR+ >0.1∗
CD45RA+RO+CCR7− 0.4 (0.2–0.7)
CXCR3+ 0.1
(0.04–0.13)
CCR5+ >0.1∗
HLA-DR+ >0.1∗
CXCR3+CCR5+ >0.1∗
CXCR3+CCR5− 0.1
(0.03–0.11)
CXCR3−CCR5+ >0.1∗
CXCR3+HLA-DR+ >0.1∗
CXCR3+HLA-DR− 0.1
(0.04–0.11)
CXCR3+HLA-DR+ >0.1∗
Data are presented as mean±standard deviation or median (25th quartile to 75th
quartile) as appropriate.
∗We did not report precise values in case of small subpopulations with frequencies
below 0.1% as median or mean value.
†CD45RA+RO−CCR7− is a naive subpopulation that had lost the expression of CCR7.
This subpopulation is small and non–well characterized.
‡CD45RA+RO+ represents a subpopulation of transition from a na¨ıve to memory
phenotype that coexpresses both CD45RA and CD45RO.
Correlations Between Circulating T-Cell Subsets
and Cardiovascular Risk Factors
First, we investigated the clinical variables that can affect the
distribution of T-cell subsets under investigation. Overall, men
and women had similar CD3+CD4+T cells (61.9±9.1% versus
59.5±11.5%, P=0.13; expressed as percentage of total CD3+
lymphocytes). Male subjects had lower TN (30.0±12.1% ver-
sus 34.6±12.9%, P=0.01; percentage of CD3+CD4+T cells),
but higher T memory cells (62.7±12.1% versus 57.8±14.4%,
P=0.01) including higher TEM (11.9±4.9% versus 10.3±3.7%,
P=0.01) and TCM (50.9±10.1% versus 47.6±12.3%, P=0.04)
compared with female (Table 4). TN were inversely correlated
with age (Spearman r=−0.31, P<0.01), while TM (Spearman
r=0.32, P<0.01) including TEM (Spearman r=0.31, P<0.01)
and TCM (Spearman r=0.22, P<0.01) or HLA-DR+T cells
(Spearman r=0.20, P<0.01) were directly correlated with
age.37,38
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Figure 4. Effector memory T cell (TEM), central memory T cell (TCM),
and memory T cell variations at several time points after tetanic vac-
cination in three healthy subjects. Dots represent subject and con-
tinuous lines show the temporal changes between the ﬁrst sampling
(before the tetanic vaccination) and the following ones at several time
point after the antigen exposure (after 2, 7, 14, and 21 days). We ob-
served a temporally limited increase in levels of TEM and a reciprocal
decrease in levels of TCM at 2 days after antigen exposure with a
subsequent decrease of TEM and increase of TCM to prevaccination
levels after 1 and 3 weeks after the exposure. Means percentage are
reported and referred to the total number of CD3+CD4+T cells (A, B).
A trend vs a signiﬁcant increase in total memory T cells have been
observed after 2 to 3 weeks from tetanic vaccination (C).
Hypercholesterolemic subjects showed increased levels of
TEM (mean±SD 12.9±1.0% versus 10.7±0.3%, P=0.02) and
HLA-DR+ T cells (6.2±0.7% versus 4.6±0.2%, P=0.03). The
presence of hypertension was associated with decreased lev-
els of TN (27.2±1.9% versus 33.6±1.4%, P<0.01) and in-
creased levels of TM (66.3±2.0% versus 58.7±1.2%, P<0.01),
including TCM (53.5±1.6% versus 43.2±1.4%, P=0.01) and TEM
(12.9±0.8% versus 10.6±0.4%, P<0.01). Smoking habits were
not associated with increased TEM levels (data not shown).
Table 4. T-Cell Principal Subpopulation Distribution
According to the Gender
T lymphocytes n183 ♂ 93 ♀ 91
CD3+CD4+
CCR7+ (%) 85.8±4.8 85.1±5.5 86.6±4.1
CCR5+ (%) 6.9±4.1 7.3±4.4 6.6±3.8
CXCR3+ (%) 26.4±9.1 27.4±10.0 25.5±8.0
HLA-DR+ (%) 4.9±2.4 5.0±2. 4.8±2.7
Naı¨ve CD45RA+RO-
CCR7+ (%)
32.3±12.7 29.9±12.1 34.6±12.9
Memory
CD45RA-RO+(%)
60.3±13.4 62.8±12.1 57.8±14.4
Central memory (%) 49.3±11.4 50.9±10.1 47.6±12.3
Effector memory (%) 11.1±4.4 11.9±4.9 10.3±3.7
Data are presented as mean±standard deviation.
Different correlations between T-cell subsets and car-
diometabolic risk factors were observed. Upon age-
adjustment, TEM were signiﬁcantly and directly correlated
with plasma total cholesterol, triglycerides, LDL cholesterol,
glycemia, body mass index, and systolic blood pressure. Fur-
thermore, subjects with metabolic syndrome or diabetes had
signiﬁcantly higher levels of TEM (14.1±4.8% and 13.8±5.1%,
respectively) compared with subjects without metabolic syn-
drome (10.8±1.2%, P=0.02) or without diabetes (10.8±1.3%,
P=0.03). No signiﬁcant correlation was observed between TCM
and cardiometabolic risk factors, while TN were inversely cor-
related only with plasma triglyceride levels. Among other main
subsets analyzed, HLA-DR+ T cells showed a direct correlation
with total cholesterol, triglycerides, and LDL cholesterol, and
an inverse correlation with HDL cholesterol.39
Correlations Between Circulating T-Cell Subsets
and Carotid IMT
Second, we investigated whether speciﬁc T-cell subsets are
associated with preclinical atherosclerosis, deﬁned by IMT at
the common carotid levels. Table 5 summarizes the correla-
tions between IMT with clinical, lipid, and metabolic variables,
and T-cell subsets. IMT correlated positively with age, sys-
tolic blood pressure, total, and LDL cholesterol, triglyceride
levels, body mass index, and glycemia, whereas IMT inversely
correlated with high-density lipoprotein cholesterol levels. As
expected, several correlations were lost after age-adjustment
of the IMT (Table 5). The analysis of CD3+CD4+T-cell subsets
revealed that TM, TEM, and HLA-DR+T cells signiﬁcantly corre-
late with IMT, whereas TN inversely correlates with IMT. As age
is the known main determinant of carotid IMT, and several
CD3+CD4+T-cell subsets and cardio-metabolic risk factors
correlated with age, the analysis of the correlation between
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Table 5. Unadjusted and Age-Adjusted Correlation Between
Intima-media thickness (IMT) and Clinical, Lipid, Metabolic
and Inﬂammatory Parameters, and T-Cell Subsets (Pearson
Correlation Coefﬁcients are Shown, n = 183)
IMT Age-adjusted IMT
r P r P
Age 0.63 <0.001 - -
Clinical variables
Systolic blood pressure 0.33 <0.001 0.07 0.38
Diastolic blood pressure 0.12 0.14 −0.04 0.61
Lipid proﬁle
Total cholesterol 0.15 0.04 −0.11 0.12
LDL cholesterol 0.19 0.01 −0.07 0.33
HDL cholesterol −0.26 0.001 −0.23 0.03
Triglyceridemia 0.25 0.001 0.06 0.42
Metabolic proﬁle
Body mass index 0.26 <0.001 0.07 0.36
Creatinine 0.34 <0.001 0.15 0.05
Glycemia 0.27 <0.001 0.14 0.07
Inﬂammatory proﬁle
CRP 0.08 0.43 −0.02 0.84
T-lymphocytes proﬁle
CD3+CD4+ −0.08 0.28 −0.11 0.11
Naı¨ve CD45RA+RO-CCR7+ −0.19 0.01 0.10 0.18
Memory CD45RA-RO+ 0.18 0.02 −0.05 0.54
Central memory T 0.06 0.42 −0.10 0.20
Effector memory T 0.40 <0.001 0.27 <0.001
CCR5+ 0.08 0.30 0.10 0.18
CXCR3+ 0.14 0.05 0.04 0.63
HLA-DR+ 0.28 <0.001 0.14 0.07
LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive
protein.
T-cell subsets and IMT was performed after age-adjustment. A
signiﬁcant direct correlation remained between age-adjusted
IMT and TEM (P<0.001), whereas only a trend for correla-
tion was observed between age-adjusted IMT and HLA-DR+
(P=0.07).
In the multiple regression analysis, age, creatinine, and TEM
cells emerged as independent predictors of IMT (Table 6). We
cannot exclude that the relatively limited number of subjects
studied could have underestimated the impact of the lipid
proﬁle on the IMT.
Table 6. Overall Multiple Regression Analysis Between
Intima-Media Thickness (IMT; dependent variable) and Age,
Gender, Smoking Habits, Clinical Parameters, and T-Cell
Subsets that Correlate with IMT in the Single Model
Model
Independent variables β P
Age 0.56 <0.01
Gender 0.05 0.67
Smoking habits −0.03 0.98
Systolic Blood Pressure −0.02 0.82
Total cholesterol −0.12 0.13
LDL cholesterol −0.11 0.11
HDL cholesterol −0.10 0.09
Triglyceridemia 0.01 0.89
Body mass index −0.05 0.51
Creatinine 0.19 <0.01
Glycemia 0.05 0.55
CD3+CD4+
Naive T cells −0.12 0.19
Central memory T cells 0.11 0.56
Effector memory T cells 0.22 <0.01
CCR5+ −0.07 0.34
CXCR3+ −0.06 0.45
HLA-DR+ 0.09 0.26
BMI indicates body mass index; HDL, high-density lipoprotein; LDL, low-density
lipoprotein.
T-Cells Subset Levels in Controls and Patients
With CAD
To further conﬁrm the association of TEM with the extent of
atherosclerosis, we studied the levels of TEM in relation to
symptomatic atherosclerosis in the coronary district. Levels of
CD3+CD4+T-cell subsets were investigated in a second inde-
pendent cohort of patients with stable and unstable manifes-
tations of CAD compared with age- and sex-matched controls.
While TN and TCM levels were not different among patients with
CSA, AMI, and controls; TEM resulted in signiﬁcant increase in
both CSA and AMI patients compared with controls (P<0.01
for both) with similar levels between CSA and AMI patients
(Figure 5 and Table 7). Similarly, HLA-DR+T cells were sig-
niﬁcantly increased in patients with CSA and AMI compared
with controls (P<0.01 for both), without differences between
CSA and AMI patients. CCR5+T cells and CXCR3+T cell levels
did not differ among controls, and patients with CSA and AMI
(Table 7).
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Figure 5. Effector memory T cells (TEM) levels are increased in pa-
tients with coronary artery disease (CAD). Representative color dot
plots from a control and patients with different CAD manifestations:
CSA, chronic stable angina; AMI, acute myocardial infarction (A). Sig-
niﬁcant increases in TEM levels were observed in patients with CSA
and AMI in comparison with controls. There were no signiﬁcant dif-
ference in levels of TEM between CSA and AMI. Kruskall-Wallis and
Dunn’s test were performed. Dots represent individual patient data;
dashed lines show median value and continuous lines show 25th and
75th percentiles (B).
Circulating TEM-Cell Subpopulations in Subclinical
Atherosclerosis and in CAD
Given the potential association between TEM and atherosclero-
sis and to further investigate whether any of the TEM subpop-
ulations could better explain this ﬁnding, the correlation be-
tween CXCR3+TEM, CCR5+TEM, HLA-DR+TEM subpopulations,
and IMT was investigated. Compared with all TEM that showed
a strong correlation with IMT (Spearman r=0.27, P<0.01),
HLA-DR+TEM showed the highest degree of correlation (Spear-
man r=0.37, P<0.01), with CCR5+TEM showing a degree of
correlation similar to TEM (Spearman r=0.25, P<0.01) while a
lower but still signiﬁcant correlation was observed also for TEM
CXCR3+TEM and IMT (Spearman r=0.15, P<0.05) (Figure 6A).
HLA-DR+TEM and CXCR3+TEM resulted the independent covari-
ates associated with IMT (Table 8). These data were supported
with the ﬁndings in patients with CAD. Indeed HLA-DR+TEM
subpopulation resulted signiﬁcantly increased in both CSA and
AMI patients compared with controls (P<0.01 for both) and,
again, HLA-DR+TEM levels were not different in CSA and AMI.
Also CXCR3+TEM were signiﬁcantly increased in CSA and AMI
patients compared with controls (overall P=0.002), whereas
no differences were observed for CCR5+TEM (Figure 6B). These
data suggest that a speciﬁc TEM subpopulation, namely HLA-
DR+TEM, which express the activation marker HLA-DR, could
better reﬂect the association with the atherogenic process.
TEM Cells Were Increased in Animal Model of
Atherosclerosis and Correlate With the Extent of
Atherosclerosis
To further characterize the presence of TEM, TCM, or TN
cells in relation to the extent of atherosclerosis, the pres-
ence of CD4+CD44−CD62L+ (TN), CD4+CD44+CD62L− (TEM),
Table 7. Circulating T-Cell Subset Levels in Controls, Patients With Chronic Stable Angina (CSA) and Acute Myocardial Infarction
(AMI)
Controls (n = 40) CSA (n = 30) AMI (n = 60)
T-lymphocytes proﬁle CD3+CD4+
Naı¨ve CD45RA+RO-CCR7+ 29.3 (18.3–35.2) 24.0 (17.9–33.8) 24.4 (19.7–32.8)
Memory CD45RA-RO+ 59.5 (15.9) 65.0 (12.4) 62.8 (12.6)
Central memory T 49.3 (14.5) 48.9 (10.9) 46.6 (11.7)
Effector memory T 9.2 (6.3–13.1) 14.7 (9.2–22.2)∗ 14.6 (10.0–17.9)†
CCR5+ 9.1 (5.9–12.3) 7.0 (5.2–17.4) 9.3 (5.4–18.3)
CXCR3+ 27.5 (22.1–33.0) 28.9 (23.7–35.4) 28.2 (21.3–31.5)
HLA-DR+ 2.2 (1.3–4.0) 5.8 (3.7–8.4)† 5.9 (4.0–9.9)†
∗<0.01 and †<0.001 vs controls. Overall P=0.0001 for Effector Memory T (TEM), and overall P=0.002 for HLA-DR+ (Kruskal-Wallis test). Results are expressed as percentage of total
CD3+CD4+T cells. Values are presented as mean (standard deviation) or as median (1◦ to 3◦ quartile) as appropriate.
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Table 8. Relative Contribution of Each Effector Memory T-Cell Subset to IMT Prediction. Data From Forced Entry Multiple
Regression Analysis With IMT as Dependent Variable and TEM, TEM-HLA-DR+, TEM-CCR5+, and TEM-CXCR3+ as Covariates Are
Shown
Model Standardized Coefﬁcient t Signiﬁcance Conﬁdence Intervals 95.0% for B
Beta Lower limit Upper limit
1 (Constant) 21.554 0.000 0.528 0.634
EM −0.227 −1.333 0.184 −0.018 0.003
TEM CCR5 −0.028 −0.381 0.704 −0.048 0.032
TEM CXCR3 0.370 2.569 0.011 0.005 0.038
TEM HLA DR 0.432 4.425 <0.001 0.072 0.189
Figure 6. Effectormemory T-cell (TEM) subpopulations correlatewith
intima-media thickness (IMT) and are increased in patients with coro-
nary artery disease (CAD). The correlation between IMT and TEM,
CXCR3+TEM, HLA-DR+TEM, and CCR5+TEM is shown in A to D (see
Methods Section for details). (E) The percentage of CXCR3+TEM, HLA-
DR+TEM, and CCR5+TEM in patients with chronic stable angina (CSA,
n = 30) or acute myocardial infarction (AMI, n = 60) and controls (n
= 40). The Kruskal-Walli test with Dunn’s comparison for all groups
was used.
and of CD4+CD44+CD62L+ (TCM) was investigated in ani-
mal models of atherosclerosis fed an atherogenic diet (Fig-
ure 7A).40 Of note, the percentage of TN signiﬁcantly de-
creased while that of TEM signiﬁcantly increased in LDL re-
ceptor knockout and apolipoprotein E knockout animals com-
pared with control animals (Figure 7B). TCM were signiﬁcantly
increased in LDL receptor knockout mice (Figure 7B). Of in-
terest, the percentage of TN was inversely correlated with
the extent of atherosclerotic lesions in the aortic sinus of
the animals (r=−0.57; P<0.01) while that of TEM was di-
rectly correlated (r=0.56; P<0.01; Figure 7C), further sup-
porting the link between TEM and atherosclerosis also in animal
models.
Discussion
Several studies have suggested a role of CD4+T cells in the
pathogenesis of atherosclerosis.2,5,41 The present study is, to
date, the largest one which investigated circulating CD4+T-
cell subsets in relation to atherosclerotic disease in humans.
The simultaneous assessment of 8 independent membrane
T-cell molecules by polychromatic ﬂow cytometry allowed to
identify more accurately and in relatively unbiased manner the
phenotype of circulating T cells.
TEM emerged as the T-cell subset with the strongest associ-
ation with atherosclerosis in carotid and coronary vascular dis-
tricts at different stages of the process. TEM were signiﬁcantly
and directly correlated with plasma total cholesterol and LDL
cholesterol, although the association between TEM and carotid
atherosclerosis was independent of the classical cardiovascu-
lar risk factors, supporting the relevance of adaptive immune
response in cardiovascular disorders.28,41
Partial characterizations of circulating T cells, which had
been previously performed, are consistent with our results:
indeed increased levels of CD28null or TCRdimT cells and de-
creased levels of CCR7 have been reported in patients with
CAD,16,27,42–44 whereas an expansion of the overall memory
T-cell population has been associated with the extent of IMT in
elderly Japanese subjects.45
TCM and TEM cells persist in the memory pool once the
antigen that elicited an immune response has been elimi-
nated. They keep memory of (1) antigen speciﬁcity, (2) array
of cytokines they had produced, and (3) the site where their
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Figure 7. Effector memory (TEM) levels are increased in animal models of atherosclerosis. Representative
color dot plots from wild-type (C57BL/6J) animals fed a chow diet, a cholesterol rich (western type, WT) diet
and from LDL receptor (LDL-R), and apolipoprotein E (Apo-E) knockout animals are shown in (A), while the
percentages of circulating na¨ıve T cells (TN: in mouse deﬁned as CD62L+CD44−), central memory T cells (TCM:
CD62L+CD44+), and memory effector T cells (TEM: CD62L−CD44−) are shown in (B) (n = 12; 3 for each group)
(*P<0.05 vs C57Bl/6J chow diet; ◦P<0.05 vs C57Bl/6J WT diet, pairwise test with Bonferroni correction). The
correlations between circulating levels of TN, TCM, and TEM and atherosclerotic plaque area at the aortic sinus
are shown in panel C (n = 12; 3 for each group, Spearman correlation coefﬁcients are shown).
effector function is
needed. Upon antigen
reexposure, TEM display
immediate effector
functions in inﬂamed pe-
ripheral tissues, whereas
TCM, activated by den-
dritic cells in secondary
lymphoid organs, gen-
erate successive waves
of effector cells.7,30
CD4+TEM are normally
excluded from resting
lymph nodes and migrate
in a CD62P-dependent
fashion into reactive
lymph nodes or to in-
ﬂamed tissue, mainly
by the expression of
CCR5 and CXCR3. The
expression of HLA-DR
constitutes a marker
of effector function
acquisition.40 The func-
tion of T cells depends
on their ability to exploit
integrins, selectins and
chemokine receptors to
extravasate and migrate
to sites where antigen
is present. Of note,
increased levels of TEM
have been previously
described in vasculitis
and chronic graft versus
host disease.46,47 Also in
these conditions, altered
levels of human TEM
were not accompanied
bysigniﬁcant changes in
TN and TCM pools.46,47
Potential Role of
TEM in the
Atherosclerotic
Process
In hypercholesterolemic
animal models it has
been observed that CCR7
knockout attenuates ath-
DOI: 10.1161/JAHA.111.000125 Journal of the American Heart Association, Vol. 1, No. 1, February 21, 2012 39
 by guest on February 22, 2012http://jaha.ahajournals.org/Downloaded from 
Effector Memory T Cells and Atherosclerosis Ammirati et al
O
R
IG
IN
A
L
 R
E
S
E
A
R
C
H
erosclerotic plaque development.17 This ﬁnding stresses the
relevance of the differentiation process of na¨ıve CD4+T cells
to effector and/or memory cells of specialized T-cell subsets
(TCM and TEM), and the CCR7-dependent T-cell and monocyte
migration during atherogensis. However, as CCR7 is expressed
on several lymphocytes, including cells that express adhesion
molecules required for homing to nonlymphoid tissues,48 the
deﬁciency of CCR7 could also impair the trafﬁcking of cells
other than CD4 lymphocytes during atherosclerosis. Therefore,
the identiﬁcation of a correlation between a speciﬁc memory
T-cell subset that lost CCR7 receptor (TEM) with atheroscle-
rosis and at the same time, the association with LDL choles-
terol levels, support the intriguing interaction between LDL
cholesterol, expansion of TEM, and atherosclerosis.5 Indeed,
experimental models have shown that CD4+T cells recog-
nize epitopes on native ApoB100 protein. Furthermore, block-
ing T-cell receptor-dependent antigen recognition by these T
cells protects against atherosclerosis.5,49 Our data demon-
strate that animal models where atherosclerosis derives from
impaired lipid metabolism and dyslipidemia, have increased
levels of TEM compared with controls that are directly asso-
ciated with the extent of the atherosclerotic lesions. While
these results can support the hypothesis of a causal link be-
tween LDL cholesterol and TEM increase, further studies are
warranted in patients to investigate whether a sustain anti-
gen stimulation, possibly mediated by LDL cholesterol, could
explain the expansion of TEM. In this context, although smok-
ing is a strong determinant of total leukocytes count and dif-
ferential leukocytes subsets, smoking habits were not asso-
ciated with increased TEM levels. This might suggests other
mechanisms associated with smoking deleterious effects on
atherosclerosis.
Of note, within the TEM subsets, we have identiﬁed subpop-
ulations with a strong correlation with the extent of atheroscle-
rosis, such as those expressing HLA-DR, CXCR3, and CCR5.
These receptors modulate the recruitment of T cells into the
atherosclerotic plaques,25,26and could thus represent an as-
set to facilitate TEM patrolling of atherosclerotic plaques at
distant sites in the organism. We further conﬁrmed previ-
ous reports that had identiﬁed the expression of HLA-DR
as a T-cell subset associated with CAD, and we identiﬁed
TEM as the CD4+T-cell subset in which HLA-DR is speciﬁcally
increased.14,50
Conclusion
Among CD4+Tcell, TEM and related TEM subpopulations are
those strongly correlated with the extent of atherosclerosis in
carotid and coronary districts. As TEM are antigen-experienced
and long-surviving cells that have lost CCR7 and express HLA-
DR, CXCR3, and CCR5, this ﬁnding strengthens the concept
that the understanding of the inﬂammatory pathogenesis of
atherosclerosis requires careful cellular subphenotyping. Fur-
thermore, the presence of increased levels of circulating TEM
in humans and the association with the extent of aortic le-
sions in animal models, suggest the possibility of targeting
plaque chemotaxis and/or antigen encountering as emerging
antiatherosclerotic strategies on the top of cardiovascular risk
factors control.25,26,49
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